Amphastar Pharmaceuticals (AMPH) Operating Expenses (2013 - 2026)

Amphastar Pharmaceuticals' Operating Expenses history runs 14 years deep, the most recent figure standing at $56.7 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 18.21% year-over-year to $56.7 million in Q1 2026; TTM through Mar 2026 was $238.5 million, a 27.96% increase from a year earlier, with the FY2025 full-year figure at $215.7 million, up 28.03% from the prior year.
• Operating Expenses retreated to $56.7 million in Q1 2026 per AMPH's latest filing, from $58.8 million in the prior quarter.
• Across five years, Operating Expenses topped out at $78.7 million in Q3 2025 and bottomed at $33.3 million in Q4 2022.
• The 5-year median for Operating Expenses is $42.1 million (2024), against an average of $44.8 million.
• Across the five-year window, Operating Expenses retreated 6.98% in 2023 and surged 66.79% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $33.3 million in 2022, then grew by 26.47% to $42.2 million in 2023, then gained by 18.86% to $50.1 million in 2024, then gained by 17.31% to $58.8 million in 2025, then slipped by 3.57% to $56.7 million in 2026.
• Per Business Quant, the three latest AMPH Operating Expenses figures stand at $56.7 million (Q1 2026), $58.8 million (Q4 2025), and $78.7 million (Q3 2025).